Year |
Citation |
Score |
2017 |
Wathen JK, Thall PF. A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clinical Trials (London, England). 14: 432-440. PMID 28982263 DOI: 10.1177/1740774517692302 |
0.651 |
|
2015 |
Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. PMID 26710211 DOI: 10.1002/cncr.29858 |
0.364 |
|
2015 |
Thall P, Fox P, Wathen J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1621-8. PMID 25979922 DOI: 10.1093/annonc/mdv238 |
0.639 |
|
2014 |
Morgan CC, Huyck S, Jenkins M, Chen L, Bedding A, Coffey CS, Gaydos B, Wathen JK. Adaptive Design: Results of 2012 Survey on Perception and Use Therapeutic Innovation and Regulatory Science. 48: 473-481. DOI: 10.1177/2168479014522468 |
0.368 |
|
2011 |
Lionberger JM, Dorcy KS, Dean C, Holm N, Scott BL, Wathen JK, Estey EH, Pagel JM. Innovative Phase I/II Statistical Design in Combination Chemotherapy That Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in De Novo Adult AML Blood. 118: 1552-1552. DOI: 10.1182/blood.v118.21.1552.1552 |
0.421 |
|
2010 |
Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4884-91. PMID 20724445 DOI: 10.1158/1078-0432.CCR-10-1177 |
0.343 |
|
2008 |
Wathen JK, Thall PF. Bayesian adaptive model selection for optimizing group sequential clinical trials. Statistics in Medicine. 27: 5586-604. PMID 18752257 DOI: 10.1002/sim.3381 |
0.562 |
|
2008 |
Thall PF, Wathen JK. Bayesian designs to account for patient heterogeneity in phase II clinical trials. Current Opinion in Oncology. 20: 407-11. PMID 18525336 DOI: 10.1097/CCO.0b013e328302163c |
0.626 |
|
2008 |
Wathen JK, Thall PF, Cook JD, Estey EH. Accounting for patient heterogeneity in phase II clinical trials. Statistics in Medicine. 27: 2802-15. PMID 17948869 DOI: 10.1002/sim.3109 |
0.651 |
|
2007 |
Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2755-63. PMID 17602081 DOI: 10.1200/JCO.2006.10.4117 |
0.576 |
|
2007 |
Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. European Journal of Cancer (Oxford, England : 1990). 43: 859-66. PMID 17306975 DOI: 10.1016/j.ejca.2007.01.006 |
0.626 |
|
2007 |
Thall PF, Cheung YK, Inoue LYT, Wathen JK. Comments on 'Continuous Bayesian adaptive randomization based on event times with covariates' [4] Statistics in Medicine. 26: 3052-3054. DOI: 10.1002/Sim.2762 |
0.504 |
|
2006 |
Chugh R, Maki RG, Thomas DG, Reinke D, Wathen JK, Patel S, Priebat DA, Meyers PA, Benjamin RS, Baker LH. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 9515. PMID 27952837 DOI: 10.1200/jco.2006.24.18_suppl.9515 |
0.339 |
|
2006 |
Maki RG, Hensley ML, Wathen JK, Patel SR, Priebat DA, Okuno S, Reinke D, Thall PF, Benjamin RS, Baker LH. A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 9514. PMID 27952836 DOI: 10.1200/jco.2006.24.18_suppl.9514 |
0.458 |
|
2006 |
Cheung YK, Inoue LY, Wathen JK, Thall PF. Continuous Bayesian adaptive randomization based on event times with covariates. Statistics in Medicine. 25: 55-70. PMID 16025549 DOI: 10.1002/Sim.2247 |
0.654 |
|
2006 |
Wathen JK, Christen JA. Implementation of backward induction for sequentially adaptive clinical trials Journal of Computational and Graphical Statistics. 15: 398-413. DOI: 10.1198/016214506X113406 |
0.462 |
|
2005 |
Thall PF, Wathen JK. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Statistics in Medicine. 24: 1947-64. PMID 15806621 DOI: 10.1002/sim.2077 |
0.624 |
|
2003 |
Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RS. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine. 22: 763-80. PMID 12587104 DOI: 10.1002/sim.1399 |
0.597 |
|
Show low-probability matches. |